ATHLONE, Ireland, April 24, 2015 (GLOBE NEWSWIRE) — Innocoll AG (Nasdaq:INNL), a specialty pharmaceutical company, today announced the pricing of its follow-on public offering of 3,321,669 American Depositary Shares (“ADSs”) at a public offering price of $9.00 per ADS. Of the ADSs in the offering, 1,999,690 ADSs are being offered by the Company and 1,321,979 ADSs are being offered by selling shareholders. The Company will not receive any proceeds from the sale of ADSs by the selling shareholders. The offering is expected to close on April 30, 2015, subject to the satisfaction of customary closing conditions.
The Company expects to receive total estimated net proceeds from this offering of approximately $16.1 million after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for general corporate purposes and the development of its products.
Piper Jaffray & Co. is acting as sole manager for the offering. The offering of these securities is being made only by means of a prospectus, copies of which can be obtained from: Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by telephone at (800) 747-3924, or by email at email@example.com.
A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission on April 23, 2015. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the offered securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Innocoll AG
Innocoll is a global, commercial-stage, specialty pharmaceutical company. The Company develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies. The Company’s late stage product pipeline is focused on addressing a number of large unmet medical needs, including: XaraColl® for the treatment of post-operative pain; Cogenzia® for the adjuvant treatment of diabetic foot infections; and CollaGUARD®, a barrier for the prevention of post-surgical adhesions. The Company’s approved products include: CollaGUARD(Ex-US), Collatamp® G, Septocoll®, RegenePro®, Collieva®, CollaCare®, Collexa®, and Zorpreva™, which are sold through strategic partnerships with various partners including Takeda, Biomet, and EUSA Pharma.
CollaRx®, Collatamp®, CollaGUARD®, Collieva®, CollaCare®, Collexa®, Cogenzia® LidoColl®, LiquiColl®, Septocoll®, and XaraColl® are registered trademarks, and CollaPress™, DermaSil™, Durieva™, and Zorpreva™ are trademarks of the Company.
Cautionary Statement on Forward-Looking Statements
This press release contains forward-looking statements. Any statements that are not of historical facts may be deemed to be forward-looking statements. You can identify these forward-looking statements by words such as ”believes,” ”estimates,” ”anticipates,” ”expects,” ”plans,” ”intends,” ”may,” ”could,” ”might,” ”will,” ”should,” ”aims,” or other similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements include statements regarding our intentions, beliefs, assumptions, projections, outlook, analyses or current expectations concerning, among other things, our results of operations, financial condition, business outlook, the industry in which we operate and the trends that may affect the industry or us, as well as the timing of the closing of the public offering or our ability to complete the public offering on the anticipated terms or at all. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that forward-looking statements are not guarantees of future performance. All of our forward-looking statements are subject to known and unknown risks, uncertainties and other factors that are in some cases beyond our control and that may cause our actual results to differ materially from our expectations, including those risks identified under the caption “Risk Factors” in the Company’s Registration Statement on Form F-1 and in other reports the Company files with the U.S. Securities and Exchange Commission, including its Annual Report of Foreign Issuer on Form 20-F. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements for any reason after the date of this press release whether as a result of new information, future events or otherwise.
Executive Vice President Business Development and
T: (215) 765-0149
Robert Flamm, Ph.D.
Senior Vice President
Russo Partners, LLC.
T: (212) 845-4226